Board Membership Profile
Dr. Ashraf F. Youssef, M.D., M.Sc. Ph.D., M.B.A., D.A.B.T(2025), is a pharmaceutical safety and drug-development executive with more than 30 years of experience spanning non-clinical research, clinical development, regulatory engagement, clinical safety and postmarketing safety/pharmacovigilance. He has led safety activities for products across multiple therapeutic areas and overseen safety responsibilities involving more than 100 established and generic products. His experience covers the product lifecycle—from early research with experimental animals and first-in-human studies through regulatory submissions, commercialization, and postmarketing surveillance.
Since returning to Takeda in 2019, Dr. Youssef has served as Functional Area Lead for Postmarketed Products. He initially oversaw more than 18 products across neuroscience, hematology, and rare diseases, and later assumed leadership for the Established Postmarketed Integrated Collaboration portfolio of more than 100 products. He led within a global, matrixed organization, with five direct reports—including four directors and one senior director—and is responsible for the oversight of deliverables from more than 20 safety scientists across three contract research organizations. His responsibilities include global safety strategy, signal evaluation, regulatory responses, periodic safety reporting, labeling, risk management, and presenting emerging safety issues to safety governance bodies.
His current leadership also encompasses operational and partner oversight. He manages scientific scope, budget negotiations, and performance of external partners and CROs, and has contributed to internal standards for benefit–risk assessment. He has applied AI to support contract-cost evaluation and established training in WHO–UMC standardized causality assessment. This experience provides a practical perspective on oversight, resource stewardship, external-partner governance, and continuous improvement.
Previously, Dr. Youssef held senior global safety roles at Shire Pharmaceuticals, Allergan, and Takeda. At Shire, he led safety activities in hematology, oncology, immunology, and rare diseases, contributing to submissions, product labeling, benefit–risk assessments, regulatory responses, inspection readiness, and independent data monitoring committees. At Allergan, he supported safety and clinical development across 27 global trials and postmarketing programs in neurology and pain. During his earlier Takeda tenure, he led and supported programs across neuroscience, oncology, renal and metabolic diseases, and gastrointestinal medicine, working with teams in the United States, Europe, and Japan.
His earlier career provides a foundation in toxicology and drug-development diligence. At TAP Pharmaceuticals, he led multiple nonclinical safety programs, managed annual program budgets of $1–2 million, negotiated project costs, and evaluated more than 15 compounds for potential in-licensing. He also served as a study director and toxicologist in academic and contract-research settings. This background equips him to assess scientific evidence, development risks, investment assumptions, and the quality of support behind strategic decisions.
Through AYPHARMA Safety Consulting, LLC, which he founded in 2011, Dr. Youssef advises on drug-development strategy, safety evaluation, signal detection, regulatory submissions, and benefit–risk assessment. His consulting work has included oncology programs, investigational therapies, licensing opportunities, and complex safety questions. He has also contributed to competitive intelligence and due diligence for in-licensing and co-development decisions.
Dr. Youssef’s professional contributions include selection as an industry representative to the International Serious Adverse Events Consortium, collaboration on international safety initiatives, and service as President of the Chicago Chapter of the Academy of Pharmaceutical Physicians and Investigators from 2006 to 2009. He has authored and coauthored multiple scientific publications in Arabic and English on toxicology, pharmacovigilance, cardiovascular safety, clinical development, and strategic partnerships. His recent 2024 and 2025 Drug Safety publications, presents a practical framework for due diligence as well as approaches to partnerships in drug development/pharmacovigilance. Further reinforcing his position as a thought leader at the intersection of scientific evaluation and pharmaceutical business strategy.
His expertise has also made him a sought-after presenter, keynote speaker, moderator, and conference chair at international scientific meetings. He has addressed audiences on subjects including benefit risk communication, signal detection, regulatory compliance, pharmaceutical partnerships, cardiovascular safety, and strategic due diligence. In 2026, his speaking engagements included discussions on cardiovascular safety throughout drug development and the role of pharmacovigilance due diligence in strategic decision making. His presentations reflect a commitment to sharing practical knowledge, encouraging thoughtful scientific debate, and helping industry professionals navigate the evolving demands of global pharmaceutical development.
Dr. Youssef’s tenured as a lecture at Medical schools at Cario and Monofia Universities, Egypt between 1987 and 1991, participated as a visiting scientist at the University of Rochester, NY between mid-1989 through 1991 and taught courses at the University of Illinois in Chicago in 1993/1994. His academic credentials reflect the breadth of his professional expertise. In addition to his medical degree, Master of Science, and Ph.D. from Cairo University, he earned a Master of Business Administration from Lake Forest Graduate School of Management in 2004. He became a Diplomate of the American Board of Toxicology in 1995 and maintained his certification through successive recertifications, including the period through 2025. This combination of medical training, advanced scientific education, professional certification, and business management expertise provides a distinctive foundation for his leadership. It enables him to evaluate organizational challenges through multiple perspectives, combining scientific rigor with operational practicality and commercial understanding.
Throughout his career, Dr. Youssef has received numerous professional honors recognizing his scientific contributions, collaborative leadership, and organizational impact. His recognition includes Takeda’s Hematology GPT Award in 2021, more than 30 We Celebrate Awards since 2019, and multiple awards from Shire, Takeda, and TAP Pharmaceuticals. These acknowledgments reflect his sustained commitment to excellence, teamwork, scientific problem solving, and professional development. Beyond formal recognition, his leadership philosophy is evident in his dedication to mentoring physicians, safety scientists, investigators, and colleagues across the United States, Europe, Japan, and other international markets.
Dr. Youssef’s professional and personal interests also reflect a broader commitment to leadership, education, and service. His early experience in academic medicine established a lifelong appreciation for teaching and knowledge sharing, while his participation in professional organizations has allowed him to support the development of future pharmaceutical leaders. Outside the pharmaceutical industry, he has demonstrated leadership through involvement in competitive cycling governance, including service with the Egyptian Cycling Federation and as the head of the commissars in the All-Africa Games. This followed natural progress as a national cycling athlete and as a life-long participants in triathlons including Ironman competitions and marathons. In parallel with his pharmaceutical career, Dr. Youssef has ongoing leadership experience in his family’s publishing business, an Arab-world publishing house focused on history, social sciences, and law. Established in 1930 and employing approximately 20 people, the business is one of his direct settings for board leadership: he currently serves as Chairman and President of its Board. This role adds experience in the stewardship and strategic cross-cultural and global direction of a longstanding enterprise and in supporting the publication and exchange of knowledge across disciplines, generations and cultures. These experiences reinforce qualities that have remained consistent throughout his career: discipline, preparation, fairness, accountability, and the ability to coordinate individuals around shared standards and objectives.
As a board member or strategic advisor, Dr. Youssef brings an evidence-based perspective to pharmaceutical development, patient safety, regulatory and operational risk, licensing and partnerships, and organizational effectiveness. He can help boards and executive teams assess scientific evidence and uncertainty, examine strategic assumptions, and consider the effects of decisions on patients, stakeholders, and long-term organizational resilience. His leadership of both a global pharmaceutical safety portfolio and a longstanding family publishing business as well as being a judge in sports gives him experience in multiple and diverse organizational contexts and board responsibilities.
His approach to leadership is grounded in integrity, accountability, humility, fairness, and service. Guided by a commitment to truth, justice, compassion, and respect for human dignity, he seeks to protect vulnerable people, challenge discrimination, mentor future leaders, and share knowledge generously. These principles inform his approach to governance: independent judgment, respect for differing perspectives, responsible stewardship, and decisions attentive to people and institutions.
Executive Leadership Summary
Character: Leads with integrity, accountability, humility, and commitment to patient protection and human dignity. Values fairness, compassionate service, and mentoring future leaders.
Knowledge: More than 3 decades of experience supported by medical, scientific, and business acumen with education in toxicology, drug development, pharmacovigilance, regulatory affairs, benefit–risk assessment, and postmarketing safety in addition to business experience in publishing and leaderships in sports.
Strategic perspective: Connects scientific evidence and uncertainty with regulatory, operational, financial, and organizational considerations. Experience includes product and portfolio oversight, licensing due diligence, external partnerships, global safety governance, cross-cultural understanding and resource management.
Communication and governance: Translates complex technical and regulatory issues into clear assessments for executives, regulators, scientific teams, and industry audiences. Brings direct board experience, supports candid discussion, and emphasizes well-informed, ethically grounded decisions that consider patient and organizational interests.
Character: Dr. Youssef demonstrates integrity, discipline, accountability, and a deep commitment to protecting patients while advancing responsible pharmaceutical innovation. His dedication to mentoring others, maintaining scientific excellence, and navigating complex professional challenges reflects a leadership philosophy grounded in ethical responsibility and continuous improvement.
Knowledge: He brings more than three decades of specialized expertise in pharmaceutical safety, toxicology, clinical development, pharmacovigilance, regulatory affairs, and global risk management. His combined medical, scientific, and business education enables him to evaluate complex challenges from clinical, operational, regulatory, and commercial perspectives.
Strategic: Dr. Youssef applies disciplined scientific judgment and business insight to guide pharmaceutical development, evaluate licensing opportunities, strengthen global safety operations, and support informed executive decisions. His experience overseeing extensive product portfolios, international partnerships, multidisciplinary teams, and regulatory initiatives positions him to contribute meaningfully to corporate governance and long-term organizational strategy.
Communication: He is an accomplished scientific communicator who translates complex medical, regulatory, and technical information into clear recommendations for executives, regulatory authorities, healthcare professionals, and industry stakeholders. Through international speaking engagements, published research, professional education, and collaborative leadership in science, business and recreational sports, he has demonstrated an ability to build understanding, encourage productive dialogue, and align diverse teams around shared objectives.
